Company intelligence / Profile preview
K36 Therapeutics
Cambridge, Massachusetts, United Statesk36tx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
K36 Therapeutics is developing KTX-1001, a first-in-class, potent, selective small molecule inhibitor of the histone methyltransferase NSD2/MMSET. The lead program is in an ongoing Phase 1 clinical trial for relapsed/refractory multiple myeloma patients with the t(4;14) translocation. The company has received industry recognition for its innovation in targeting previously "undruggable" epigenetic drivers of cancer.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on K36 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K36 Therapeutics.